Please login to the form below

Not currently logged in
Email:
Password:

Amgen buys Irish Pfizer plant

Amgen is to purchase an Irish manufacturing facility from Pfizer, with the jobs of 280 workers set to be retained

California-based biotech Amgen is to purchase Pfizer's manufacturing facility in County Dublin, Ireland, taking over a workforce of 240 Pfizer employees, with 40 workers to remain employed by Pfizer.

Pfizer had previously announced the closure of the facility as part of plans to streamline the company following its £68bn acquisition of Wyeth.

Financial details of the deal remain undisclosed, with Amgen to manufacture Pfizer products at the facility for an interim period while Pfizer leases a portion of the facility from Amgen.

Following the interim period, Amgen said it intends to 'develop the capability to formulate and fill its biological products at the site,' which has freeze-dry product and liquid vial filling operations.

The company said it also intends to expand manufacturing capabilities at the plant in the future.

Madhu Balachandran, senior vice president, Amgen Manufacturing, spoke of the deal's potential for Amgen to grow on a global level: "As we expand internationally, the Dublin site will help us deliver a growing supply of Amgen medicines for patients worldwide."

Barry O'Leary, CEO of Industrial Development Authority (IDA) Ireland – the agency responsible for developing industry opportunities in the country – commented on the positive effect of the deal for Ireland.

"This investment by Amgen... gives a substantial boost to Ireland's life sciences sector," he said.

"The retention of the 240 jobs by Amgen and the 40 staff who will remain employed by Pfizer, in Dun Laoghaire, is also very welcome news for staff and management here."

14th March 2011

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Fishawack Group of Companies

The Fishawack Group of Companies is one of the largest independent medical communications and medical marketing specialists, with teams in...

Latest intelligence

Report: Achieving launch excellence in the challenging healthcare markets of today
Our in-depth report is based on original data and expert interviews, which coupled with our own experience, ensures we give you the best recommendations for achieving launch success in challenging...
What is blockchain and why should i care - Richard Springham
Four Health - Emerging Technologies The power of blockchain lies in the fact it can prove that a unique event occurred at a certain time with out the need to...
NHS medicines optimisation milestone
Steve How, Paul Midgley and Oli Hudson, of the Wilmington Healthcare Consulting Team, explore the implications of Adalimumab’s recent European patent expiry...

Infographics